Noha Al-Otaibi

463 total citations
8 papers, 85 citations indexed

About

Noha Al-Otaibi is a scholar working on Molecular Biology, Immunology and Infectious Diseases. According to data from OpenAlex, Noha Al-Otaibi has authored 8 papers receiving a total of 85 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Molecular Biology, 3 papers in Immunology and 2 papers in Infectious Diseases. Recurrent topics in Noha Al-Otaibi's work include Medicinal Plants and Bioactive Compounds (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Immunotherapy and Immune Responses (2 papers). Noha Al-Otaibi is often cited by papers focused on Medicinal Plants and Bioactive Compounds (3 papers), SARS-CoV-2 and COVID-19 Research (2 papers) and Immunotherapy and Immune Responses (2 papers). Noha Al-Otaibi collaborates with scholars based in Saudi Arabia, United Kingdom and Sweden. Noha Al-Otaibi's co-authors include Mohammad Azharuddin, Hassan Rahmoune, Nigel K.H. Slater, Jorma Hinkula, Juliana S. Cassoli, Daniel Martins‐de‐Souza, Maria Sunnerhagen, Daniel Aili, Claudia Devito and Robert Selegård and has published in prestigious journals such as PLoS ONE, Cellular Physiology and Biochemistry and Journal of Immunology Research.

In The Last Decade

Noha Al-Otaibi

7 papers receiving 83 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Noha Al-Otaibi Saudi Arabia 5 30 22 17 14 10 8 85
David Lembo Italy 3 53 1.8× 16 0.7× 11 0.6× 8 0.6× 8 0.8× 5 113
Daniela S. Reis Brazil 6 59 2.0× 29 1.3× 26 1.5× 9 0.6× 13 1.3× 7 152
Syed Saoud Zaidi Pakistan 5 25 0.8× 23 1.0× 16 0.9× 40 2.9× 8 0.8× 9 152
Andrew Claxton United Kingdom 3 60 2.0× 20 0.9× 65 3.8× 30 2.1× 20 2.0× 4 152
Nicholas P. Dylla United States 6 90 3.0× 16 0.7× 8 0.5× 6 0.4× 9 0.9× 6 146
Minh Quan Lê United States 7 49 1.6× 21 1.0× 6 0.4× 13 0.9× 2 0.2× 15 145
Asghar Abdoli Iran 4 60 2.0× 13 0.6× 11 0.6× 5 0.4× 6 0.6× 6 135
Z. Xu China 8 31 1.0× 20 0.9× 29 1.7× 6 0.4× 7 0.7× 17 137
Bret L. Pinsker United States 5 27 0.9× 18 0.8× 24 1.4× 6 0.4× 3 0.3× 11 112
Vicente Merino‐Bohórquez Spain 6 25 0.8× 8 0.4× 10 0.6× 15 1.1× 7 0.7× 21 135

Countries citing papers authored by Noha Al-Otaibi

Since Specialization
Citations

This map shows the geographic impact of Noha Al-Otaibi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Noha Al-Otaibi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Noha Al-Otaibi more than expected).

Fields of papers citing papers by Noha Al-Otaibi

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Noha Al-Otaibi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Noha Al-Otaibi. The network helps show where Noha Al-Otaibi may publish in the future.

Co-authorship network of co-authors of Noha Al-Otaibi

This figure shows the co-authorship network connecting the top 25 collaborators of Noha Al-Otaibi. A scholar is included among the top collaborators of Noha Al-Otaibi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Noha Al-Otaibi. Noha Al-Otaibi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
2.
Azharuddin, Mohammad, Claudia Devito, Maria Sunnerhagen, et al.. (2022). Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein. Vaccines. 10(4). 504–504. 7 indexed citations
3.
Azharuddin, Mohammad, et al.. (2022). Efficacy and Immune Response Elicited by Gold Nanoparticle- Based Nanovaccines against Infectious Diseases. Vaccines. 10(4). 505–505. 41 indexed citations
4.
Al-Otaibi, Noha, et al.. (2021). Disaccahrides-Based Cryo-Formulant Effect on Modulating Phospho/Mitochondrial Lipids and Biological Profiles of Human Leukaemia Cells. Cellular Physiology and Biochemistry. 55(2). 206–221. 1 indexed citations
5.
Al-Otaibi, Noha, Nigel K.H. Slater, & Hassan Rahmoune. (2018). Cryopreservation of Red Blood Cells. Methods in molecular biology. 1916. 233–238. 5 indexed citations
6.
Al-Otaibi, Noha, Juliana S. Cassoli, Nigel K.H. Slater, & Hassan Rahmoune. (2018). Molecular Characterization of Human Leukemia 60 (HL-60) Cells as a Model of Acute Myelogenous Leukemia Post Cryopreservation. Methods in molecular biology. 1916. 239–247. 4 indexed citations
7.
Al-Otaibi, Noha, Juliana S. Cassoli, Daniel Martins‐de‐Souza, Nigel K.H. Slater, & Hassan Rahmoune. (2018). Human leukemia cells (HL-60) proteomic and biological signatures underpinning cryo-damage are differentially modulated by novel cryo-additives. GigaScience. 8(3). 8 indexed citations
8.
Al-Otaibi, Noha, Nigel K.H. Slater, & Hassan Rahmoune. (2016). Salidroside as a Novel Protective Agent to Improve Red Blood Cell Cryopreservation. PLoS ONE. 11(9). e0162748–e0162748. 19 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026